In this context, there are two important biomarkers representing different molecular attributes of glioma: (1) O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status and (2) isocitrate dehydrogenase (IDH) mutation status. This evidence concerns the gene IDH3A and central nervous system cancer.